A spontaneous mutant of a derivative of Escherichia coli strain K-12 resistant to 50 ug of ketomycin per ml was selected. The mutant displayed a two-to threefold derepression of the isoleucine-valine biosynthetic enzymes and a reduced growth rate in minimal medium. The lesion was found to lie in the gene (ilvE) specifying transaminase B and resulted in an isoleucine limitation. The presence of exogenous isoleucine during growth in minimal medium restored normal phenotypic properties. The reduced transaminase B activity is responsible for the resistance to ketomycin. An unusual derepression of the acetohydroxy acid synthetase in response to an isoleucine limitation was noted.
The antibiotic ketomycin, produced by Streptomyces antibioticus, was first described (W. D. Celmer, Belgian Patent 644682, 1964) as a 3-cyclo-hexeneglyoxylic acid. Keller-Schierlein et al. reported that ketomycin inhibits the growth of Bacillus subtilis in a chemically defined medium and that the inhibition can be reversed competitively by some biosynthetic intermediates, leading to formation of the branched-chain amino acids (6) . Isoleucine was reported to reverse the inhibition noncompetitively. Specifically, ketomycin was demonstrated to inhibit, competitively, the conversion of a-keto-,B-methylvalerate to isoleucine by means of an amino acid dehydrogenase activity. In the same studies, Keller-Schierlein et al. found that B. subtilis can convert ketomycin to 3-cyclohexeneglycine, which inhibits growth and can be counteracted by the same compounds that reverse ketomycin inhibition. The synthesis of 3-cyclohexeneglycine and its properties as an isoleucine antagonist in Escherichia coli were reported earlier in studies of growth inhibition (5). 3-Cyclohexeneglycine competitively inhibits threonine deaminase in a crude extract, but it is only slightly inhibitory to isoleucyl-transfer ribonucleic acid (tRNA) synthetase even when present in a 10-fold higher concentration than isoleucine (6) . Ketomycin the action of the analogue (K. Poralla, personal communication). All of the isoleucine excreters showed resistance to 3-cyclohexeneglycine as well. Ketomycin, although its antagonism is reversed by all of the keto acids and amino acids in branched-chain amino acid biosynthesis, appears to exert its toxic effect only after its conversion to 3-cyclohexeneglycine, an analogue of isoleucine.
In E. coli K-12, transaminase B is responsible for the conversion of a-keto-,3-methylvalerate to isoleucine. We have selected a spontaneous, ketomycin-resistant mutant of a strain of E. coli derived from strain K-12. The biochemical lesion is in transaminase B and leads to excretion of a-keto acids. The mutant remains sensitive to 3-cyclohexeneglycine. The observations support a mechanism of resistance characterized by a limited capacity to convert ketomycin to 3-cyclohexeneglycine, which is the toxic product of ketomycin metabolism.
MATERIALS AND METHODS
Organisms and cultivation conditions. The strains used in this study are listed in Table 1 . E. coli strain CU2001, a rbs-derivative of strain K-12 (prepared by D. McGilvray), was employed as the parent strain. A mineral salts-glucose medium (minimal medium) previously described (12) was used, with supplements as described below, for all studies requiring cell growth.
Mutant selection technique. Fifty separate tubes containing 1 ml of minimal medium were inoculated from single colonies of strain CU2001 growing on minimal agar plates. These tubes were incubated for 24 h at 37 C in a tissue culture roller drum (New Brunswick Scientific Co., New Brunswick, N.J.) to Preparation of crude extracts and enzymatic assays. Crude extracts were prepared as previously described from exponential-phase cultures of the strains being examined (13) . Protein determinations were made by the biuret method (8) .
Threonine deaminase activity was measured by the colorimetric method described by Szentirmai and Umbarger (13) and acetohydroxy acid synthetase activity was measured by the method of St0rmer and Umbarger (13) . The colorimetric procedure of Parsons and Burns (9) was used to assay ,B-isopropylmalate dehydrogenase activity. A colorimetric assay of transaminase B activity was accomplished by use of a modification of the procedure of Duggan et al. (3) . In this procedure, the 2, 4-dinitrophenylhydrazone of a-keto-fl-methylvalerate was extracted as it was formed. A 1-ml enzyme assay mixture contained 100 Almol of tris(hydroxymethyl)aminomethane-hydrochloride buffer (pH 8.0), 0.1 Amol of pyridoxal phosphate, 15 gmol of a-keto-glutarate, 50 ;1mol of L-valine or 25 gmol of L-isoleucine, 1 or 2 mg of crude extract protein, and distilled water. A control mixture contained everything except the substrate valine or isoleucine. Assay mixtures were incubated at 37 C for 15 min and the reactions were terminated by addition of 0.1 ml of 50% trichloroacetic acid. A suitably sized sample of this mixture was diluted to 1.0 ml and mixed with the 2,4-dinitrophenylhydrazine reagent (3) to initiate the formation of the keto acid derivative.
The 5-min extraction of the 2,4-dinitrophenylhydrazones during their formation recommended by Duggan et al. (3) was accomplished by placing tubes containing the extraction components in a test tube rack fastened to the center vibrator shaft of a Rotaiy Evapo-Mix tube flash evaporator (Buchler Instruments, New York, N.Y.). This apparatus created a vortex action in each tube. The speed of rotation was adjusted so that an emulsion was clearly evident for the duration of the extraction period. Routinely, 12 tubes were conveniently handled by this method.
Portions of the toluene layers were removed and extracted with Na2CO3 in the same manner described above and centrifuged at low speed to separate the layers. Samples of the Na2CO3 layers were removed and transferred to another test tube, and NaOH was added to develop the color. After 10 min, the color intensity was measured spectrophotometrically at 540 nm. Standards prepared from a-keto-,B-methylvalerate and a-keto-isovalerate were treated by the same extraction procedure. The amino-acyl-tRNA synthetase activities for the branched-chain amino acids were assayed by procedures described earlier (2).
Transductions. All transduction experiments were conducted with the transducing phage P1 according to the method described by Lennox (8) . Strain construction was performed with ultraviolet-irradiated P1 phage.
Chemicals. All commercially available chemicals used in the study were of reagent grade or of the highest purity otherwise obtainable. K. Poralla and W. Shieve kindly supplied ketomycin (3-cyclohexeneglyoxylic acid) and 3-cyclohexeneglycine, respectively.
RESULTS
Mutant selection and growth response. On the basis of their excretion properties, five distinct classes of spontaneous mutants of strain CU2001 that are resistant to 50 jg of ketomycin per ml have been obtained. The classes are listed in Table 2 . Isolates of class 1 which did not excrete material feeding any of the test organisms were most common (33 of 47). Strain CU2588, the mutant described in this study, was the sole isolate from class 5. It excreted products satisfying the growth-factor requirements of isoleucine, valine, and leucine auxotrophs. The growth rate of strain CU2588 in 1/47 ilvA unsupplemented minimal medium was less than that of the parent strain CU2001 (Fig. 1) . Addition of isoleucine alone restored the normal growth rate. However, addition of a-aminobutyrate, which is readily converted to the isoleucine precursor a-ketobutyrate, failed to restore a normal growth rate to the mutant. The ketomycin-resistant mutant retained a sensitivity to valine but appeared to be slightly less sensitive than the parent strain.
Phenotypic response of the isoleucine-, valine-, and leucine-forming enzymes to the repression signals. The relationship of the structural genes for the biosynthetic enzymes, their regulatory loci, and the enzymes involved in the biosynthesis of the branched-chain amino acids is shown in Fig. 2 . One enzyme from each of the three operons involved in isoleucine, valine (11) , and leucine biosynthesis (with the exception of the inducible isomeroreductase [1 ] ) was examined to assess what effects the mutation to ketomycin resistance had upon regulation of synthesis of the biosynthetic enzymes (Table 3) . Consistently, threonine deaminase and acetohydroxy acid synthetase in the ketomycin-resistant strain CU2588 were observed to have two-to threefold greater specific activity than the parent strain, CU2001, when grown in unsupplemented minimal medium. 6l-Isopropylmalate dehydrogenase appeared to be slightly elevated (50%) in the mutant. When grown in the presence of L-isoleucine (4 x 10-4 M), L-valine (1.2 x 10-3 M), and L-leucine (4 x 10-4 M), these enzymes were repressed to parental, wild-type repressed levels. Threonine deaminase and acetohydroxy acid synthetase in strain CU2588 displayed normal response to feedback inhibition by isoleucine and valine, respectively. Examination of the branchedchain amino-acyl-tRNA synthetase activities yielded no evidence of enzyme alterations. Thus, the derepression of the isoleucine-valine biosynthetic enzymes was not due to altered amino acid-activating enzyme activities nor to biosynthetic enzymes with altered response to feedback inhibition. The low-grade derepression was the only difference noted between the mutant and wild type. It seemed unlikely that the analogue resistance could be due solely to the two-to threefold derepression observed.
Linkage of ketomycin resistance to ilv to P1 transduction. Phage lysates were prepared on strain CU2588 and used to determine cotransduction frequency of the excretion properties (Exc) accompanying transfer of the resistance marker, which was designated ilv-503 (T'able 4). Linkages by co-transduction frequency to ilvA451, ilvD452, and ilvE453 were 96, 98, and 100%, respectively. The rbs marker in strain CU2588 was also used as an unselected marker. The co-transduction frequencies of the rbs marker given in Table 4 were in good agreement with results normally obtained in this laboratory. The mutation for ketomycin resistance lies, therefore, very closely linked to the ilv region of the E. coli chromosome. Furthermore, among 200 ilvE+ recombinants, all exhibited the Exc+ character of the donor (Table 4) . Symbol (strain CU2001): 0, minimal medium. Klett readings were made with a no. 42 filter. The lag noted in the growth of strain CU2001 was due to the fact that the inoculum was taken from a culture that had reached the stationary phase, whereas the inoculum of the slower growing strain CU2588 was still in exponential phase when removed. [deaminating] ); AHS I, end product-inhibited acetohydroxy acid synthetase; AHS II, end product-noninhibited acetohydroxy acid synthetase; IR, acetohydroxy acid isomeroreductase; DH, dihydroxy acid dehydrase; TRA, transaminase A; TRB, transaminase B; TRC, transaminase C; IPMS, a-isopropylmalate synthetase; ISO, isopropylmalate isomerase; IPMD, 8-isopropylmalate dehydrogenase. The ilv and leu genes corresponding to these enzymes are indicated below the scheme. Genes ilvP, ilvO, and leuO are repression recognition sites, ilvQ is the induction recognition site, and ilvY is the gene for the positive control element needed for induction of isomeroreductase activity. The gene order in each cluster is the reverse (i.e., left to right is counterclockwise) of the way it is usually represented on the E. coli chromosome map. Adapted from Taylor (14) and Pledger and Umbarger (10) .
Several Ilv+, Exc+ transductants were selected from the cross with strain CU8 (ilvA451) as the recipient, and two (strains CU8506 and CU8507) were examined for response of the isoleucine-valine biosynthetic enzymes under conditions of growth in minimal medium and in minimal medium supplemented with isoleucine, valine, and leucine (Table 5) . Threonine deaminase and acetohydroxy acid synthetase activities in both strains CU8506 and CU8507 were about twice those in the parent (strain CU2001) when grown in minimal medium. Repressed levels of the isoleucine and valine biosynthetic enzymes were normal in all three strains. Thus, the phenotypic properties attributed to the mutation causing ketomycin resistance appear to be tightly linked to the ilv region by P1 transduction. Furthermore, excretion properties are a good indication of the presence of the ilv-503 lesion.
Examination of culture filtrates for evidence of excreted isoleucine, valine, and leucine. Cell-free culture filtrates of strain CU2001 and strain CU2588 were passed over a Dowex-50 column (H+-form) to adsorb amino acids. The purpose was to distinguish whether excretion products from strain CU2588 were the keto acid precursors (a-keto-fl-methylvalerate, a-ketoisovalerate, and a-ketoisocaproate) or the respective amino acids (isoleucine, valine, and leucine). The fraction binding to Dowex-50 was eluted with NH,OH, evaporated to dryness, and redissolved. This fraction, potentially containing amino acids but not keto acids, was tested for the presence of isoleucine, valine, and leucine by ability to feed the respective auxo-VOL. 3, 1973 on November 6, 2017 by guest http://aac.asm.org/ trophic mutants (Table 6 ). The results show that a concentrated culture filtrate of strain CU2588 applied to agar plates seeded with the indicated auxotrophs supported the growth of ilvA and ilvD mutants but not that of an ilvE mutant, and it inhibited the growth of strain K-12 (sensitive to valine). However, the fraction of culture filtrate that was bound to Dowex-50 did not stimulate growth of any of the auxotrophs nor did it inhibit the growth of strain K-12. This observation, together with the fact that strain CU2588 did not feed an ilvE mutant but did feed an ilvD mutant, suggests that the keto acid precursor (a-keto-fl-methylvalerate) of isoleucine is excreted rather than isoleucine. The data suggesting excretion of a-keto acid analogues of isoleucine and valine, the inability of isoleucine precursors to restore the normal growth rate to strain CU2588 whereas isoleucine does, and the genetic linkage data all indicated that the site of the mutation might be the ilvE gene specifying transaminase B.
Examination of transaminase B activity. The parent strain CU2001 and the ketomycinresistant mutant CU2588 were both assayed for transaminase B activity. Transaminase B activity in crude extracts of strain CU2588 was barely measurable (Table 7) . Higher protein concentrations in the extracts resulted in higher specific activities of the mutant enzyme. Preparation of the mutant extract at room temperature instead of 0 C, or growth of the cells at 30 C instead of 37 C, did not show any stabilizing effect on the activity.
Response of the branched-chain amino acid biosynthetic enzymes in the ketomycinresistant strain to exogenous isoleucine. Growth studies showed that strain CU2588 growing in minimal medium underwent a slight isoleucine limitation which was evidenced by a longer generation time than that of the parent, and that the normal growth rate was restored by the addition of isoleucine alone. The presence of a reduced transaminase B activity is consistent with an isoleucine limitation. It was of obvious interest to determine whether the other phenotypic properties of the mutant were also restored to normal by the presence of isoleucine during growth. The results of such an experiment showed the derepression noted earlier for enzymes under control of ilvO, ilvP, and leuO in strain CU2588 growing in minimal medium ( Table 8 ). The presence of isoleucine essentially restored the enzyme activities of the ketomycinresistant mutant to levels of activity observed for the parent strain under the same growth conditions. In the presence of all three of the branched-chain amino acids, the operons in both the parent and the mutant were repressed to the same levels. Effects of ketomycin and 3-cyclohexeneglycine on growth. Since the mutation causing resistance to ketomycin in strain CU2588 lies in the ilvE region, one might predict that this strain should remain sensitive to cyclohexeneglycine. Minimal agar plates seeded with the parent strain, CU2001, and with the mutant strain, CU2587, were used to test these strains for sensitivity to ketomycin and 3-cyclohexeneglycine. The parent strain displayed large zones of growth inhibition by crystals of ketomycin and by crystals of cyclohexeneglycine placed on the surface of the seeded plate. The mutant strain CU2588 showed no zone of inhibition in the presence of ketomycin but displayed the same inhibition by cyclohexeneglycine that was observed in the parent strain.
DISCUSSION
The lesion (ilvE503) causing resistance to ketomycin in strain CU2588 has resulted in a transaminase B activity that is very low in vitro. Because of the instability of the altered transaminase B, it has not been possible to determine the precise manner in which the enzyme has changed. It is assumed that a similar, low level of activity occurs in vivo. The extent to which an isoleucine limitation occurs is governed by the in vivo rate of conversion of a-keto-B3-methylvalerate to isoleucine. Since the cells grow slowly in minimal medium and isoleucine addition restores the wild-type growth response, an isoleucine limitation obviously occurs in vivo. Growth studies indicate that only isoleucine is limiting, presumably because it is entirely dependent upon transaminase B activity for the final step in its synthesis. Appreciable valine and leucine limitations may not occur, since the transaminase C converts a-keto-isovalerate to valine and transaminase A converts a-keto-isocaproate to leucine.
Derepression of the enzymes controlled by the repression recognition site, ilv 0, is expected because of an isoleucine limitation. Consequently, the malfunction of transaminase B results in an accumulation of a-keto-fl-methylvalerate which may enhance resistance to ketomycin by competing for the active site on the altered transaminase B. Such a model for resistance predicts that ketomycin is not converted to cyclohexeneglycine in vivo; therefore, strain CU2588 should remain sensitive to cyclohexeneglycine. Retention of cyclohexeneglycine sensitivity was indeed observed. It is therefore concluded that a low level of transaminase B activity is one mechanism by which E. coli may become resistant to the action of ketomycin.
Less easily explained in view of earlier observations (4) is the derepression of the ilvP-controlled acetohydroxy acid synthetase. This enzyme has been shown to respond multivalently to limitations of valine and leucine but not isoleucine (4) . However, the derepression of acetohydroxy acid synthetase observed in strain 
